Biogen Idec, Inc. (Massachusetts) Reports First Quarter 2010 Results TYSABRI(R) Revenues Increase 32% Year over Year

April 20, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its first quarter 2010 results.

Twitter
LinkedIn
Facebook
Email
Print

Earnings

Biogen